Dermatology care for skin of color can be improved by understanding inflammation-driven hyperpigmentation, safer treatments, and addressing education gaps that delay diagnosis and worsen outcomes.
Published: 5/27/2026
Researchers at Northwestern University have uncovered a surprising new role for montelukast that could reshape how oncologists approach immunotherapy resistance.
Published: 5/20/2026
FDA approves benralizumab for hypereosinophilic syndrome, driven by NATRON phase 3 clinical trial data showing fewer flares and improved fatigue.
Published: 5/15/2026
FDA approval brings AstraZeneca’s Breztri Aerosphere triple asthma inhaler for patients 12 years and older, boosting lung function fast and simplifying daily control.
Published: 5/8/2026
This is the second complete response letter the manufacturer has received for this treatment regimen.
Published: 4/13/2026
Community pharmacists boost asthma control by improving adherence, inhaler technique, and access—cutting exacerbations and emergency department visits.
Published: 3/20/2026
New once-daily oral peptide blocks IL‑23 receptor, delivering high skin clearance and strong safety for moderate-to-severe plaque psoriasis in ages 12+.
Published: 3/18/2026
FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.
Published: 3/13/2026
New AAAAI data spotlight oral remibrutinib for CSU, next-generation peanut allergy therapies, infant microbiome prevention, and GLP‑1 receptor agonists linked to fewer asthma flares.
Published: 3/6/2026
VOYAGE trial data show dupilumab improves pediatric asthma control and lowers exacerbations versus placebo, with higher remission and lung function gains earlier.
Published: 3/2/2026
![Patient with hives (chronic spontaneous urticaria [CSU]) -- Image credit: suriya | stock.adobe.com](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/f7c28cd2ba0b3498c4a0de7219e357228265f4ac-5472x3648.jpg?w=400&h=225&fit=crop&q=80&auto=format)
Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.
Published: 2/27/2026
Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.
Published: 2/27/2026
The FDA issued a drug safety communication regarding rare but severe pruritus associated with discontinuation of long-term use of cetirizine or levocetirizine.
Published: 2/19/2026
FDA approves difamilast (Adquey), a topical PDE4 inhibitor, expanding nonsteroidal options for mild to moderate atopic dermatitis in dermatology patients 2 years and older.
Published: 2/18/2026
The updates allow for patients of reproductive age to complete pregnancy tests at home during or after treatment.
Published: 2/11/2026
Research reveals that patients with asthma who experience symptoms of depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.
Published: 1/30/2026
New research reveals how specific gut bacteria in infants may reduce the risk of allergies and asthma, offering potential preventive strategies.
Published: 1/26/2026
Rocatinlimab shows promise in treating moderate-to-severe atopic dermatitis, offering significant symptom relief.
Published: 1/22/2026